Imugene’s latest blood cancer trial is turning heads—82% of patients who didn’t respond to CAR-T therapy saw their cancer shrink or even disappear after trying azer-cel. Some who started with just a partial response are now totally cancer-free! And in patients new to CAR-T, the response rate is even higher at 83%. One patient has stayed cancer-free for over 19 months. This could be a real game-changer for blood cancer treatments! #Health #BodyHealth #CancerResearch